Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 746
- Registration Number
- NCT03748134
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
🇧🇪Cliniques Universitaires Saint-Luc Av., Bruxelles, Hippocrate 10, Belgium
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 650
- Registration Number
- NCT03745170
- Locations
- 🇨🇳
The Fifth Medical Center,Chinese PLA General Hospital, Beijing, Beijing, China
A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT03717103
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
- Conditions
- Squamous NSCLC
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 357
- Registration Number
- NCT03629925
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
- Conditions
- Lung Neoplasms
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 397
- Registration Number
- NCT03607539
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, China
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT03568539
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT03545971
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT03366688
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT03228836
- Locations
- 🇨🇳
Jiangsu Provincial Hospital, Nanjing, Jiangsu, China
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 290
- Registration Number
- NCT03150875
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, China
🇨🇳The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang, China